Introduction
============

The porcine circovirus (PCV) is a small non-enveloped single-stranded circular DNA virus of swine. Currently, three major PCV2 genotypes have been recognized: PCV type 1 (PCV1), PCV2 type 2 (PCV2), and PCV type 3 (PCV3) ([@ref-27]; [@ref-28]). PCV1 is non-pathogenic to pigs, whereas PCV2 is the primary causative agent of porcine circovirus-associated disease (PCVAD) in growing pigs, which includes systemic, respiratory and enteric manifestations, and PCV3 is associated with porcine dermatitis and nephropathy syndrome (PDNS) ([@ref-27]).

Currently, PCV2 is the primary causative agent of swine viral disease worldwide, which has resulted in considerable economic loss since it was first identified in Canada in 1991 ([@ref-15]; [@ref-21]; [@ref-3]). The viral genomes range from 1,766 to 1,768 nucleotides (nt) in length and contain four major identified open reading frames (ORFs) (ORF1--ORF4). ORF2 encodes the capsid protein (Cap), which is the only structural protein of PCV2 and is related to viral antigenicity; hence, the gene encoding the Cap protein is suitable as a phylogenetic and epidemiological marker ([@ref-12]; [@ref-5]; [@ref-19]). Currently, at least five distinct genotypes have been described in swine based on the ORF2 sequence, which have been classified as PCV2a, PCV2b, PCV2c, PCV2d, and PCV2e ([@ref-31]; [@ref-16]; [@ref-35]; [@ref-6]; [@ref-20]). PCV2e is a new genetic group which was recently proposed by [@ref-6]. Currently, PCV2a, PCV2b, and PCV2d are found globally, whereas PCV2c has only been identified in Denmark and Brazil ([@ref-7]; [@ref-10]). PCV2e is a new genotype that has been circulating in the USA since 2015, the ORF2 sequences of which have 12 or 15 additional nts compared to those of PCV2a--PCV2d ([@ref-16]; [@ref-6]).

PCV2 was first reported in China in 1999, and has become the causative agent of one of the country's most serious swine diseases ([@ref-22]; [@ref-32]; [@ref-34]; [@ref-13]; [@ref-19]). Previous studies showed that various genotypes, including PCV2a, PCV2b, and PCV2d are present in China. Among these genotypes, PCV2b and PCV2d have been predominant in China since 2004 ([@ref-22]; [@ref-32]; [@ref-34]; [@ref-13]; [@ref-19]). Recently, several groups showed that PCV2 isolates in pig farms had recombined owing to the co-existence of different PCV2 genotypes ([@ref-17]; [@ref-4]; [@ref-18]; [@ref-30]; [@ref-1]). Despite continuous reports of newly emerging strains worldwide, information on the genetic variation of PCV2 in the Fujian province is limited. Therefore, to understand the current molecular epidemiology of PCV2 in Southeast China, the objective of the present work was to investigate the epidemiological and evolutionary characteristics of PCV2 in the Fujian province from 2013 to 2017.

Materials and Methods
=====================

Animal ethics
-------------

Sampling procedures were approved by the Animal Ethics Committee of the South China Agricultural University, with a reference number of SCAU-AEC-2014-10.

Clinical samples
----------------

Six hundred and eighty-five clinical samples (blood, lungs, kidneys, livers, and lymph nodes) were collected from unthrifty pigs (4--10 weeks of age) in different farms of Fujian province, China, between 2013 and 2017. In particular, samples were collected from 32 farms in Longyan (196 samples), 14 farms in Zhangzhou (105 samples), eight farms in Xiamen (75 samples), five farms in Fuzhou (54 samples), four farms in Ningde (40 samples), 14 farms in Nanping (92 samples), four farms in Sanming (40 samples), five farms in Quanzhou (45 samples), and four farms in Putian (38 samples) from 2013 to 2017 ([Fig. 1](#fig-1){ref-type="fig"}). These pigs were suspected to have clinical signs of Postweaning Multisystemic Wasting Syndrome (PMWS) and/or PDNS. In addition, 200 water samples were collected from the river or pool covering a geographic area of about 5 km^2^ near every pig farm.

![Locations of PCV2-positive swine farms where samples were collected in Fujian Province.](peerj-06-4476-g001){#fig-1}

Polymerase chain reaction (PCR) amplification and nucleotide sequencing
-----------------------------------------------------------------------

Total viral DNA was extracted from tissue samples using DNA extraction kit ver.3.0 (TaKaRa, Dalian, China) following the manufacturer's protocol. ORF2 was amplified from the extracted DNA using specific primers according to previous studies ([@ref-9]). PCR products were purified using the gel extraction kit (Tiangen Biotech Co. Ltd., Beijing, China) and cloned into the pGEM-T Easy vector (Promega). Recombinant clones were sequenced by Sangon Biotech (Shanghai) Co. Ltd. Each fragment was independently sequenced at least thrice.

Phylogenetic analysis
---------------------

Ninety-five ORF2 genes of PCV2 isolates were identified in the Fujian province during 2013--2017. Representative PCV2 sequences, including PCV2a, PCV2b, PCV2c, PCV2d, and PCV2e isolates in the GenBank, were used for sequence alignments and phylogenetic analyses.

Multiplex sequencing alignments were performed using CLUSTAL X (version 1.83). The phylogenetic tree was constructed using the neighbor joining (NJ) method with MEGA 6.0, the maximum composite likelihood model, and a bootstrap confidence value of 1,000 replicates.

Recombination analysis
----------------------

To detect putative recombination events in PCV2, recombinant strains were investigated on the complete genome database using a recombination detection program (RDP v.4.24) ([@ref-25]) as described by [@ref-30]. Briefly, seven methods (RDP, GeneConv, BootScan, MaxChi, Chimera, SiScan, and 3Seq) were used for preliminary scan and only events detected by more than two methods with a highest acceptable *p*-value of 0.01 were considered. The recombination event was further confirmed using SimPlot program (v.3.5.1) and boot scanning analysis was performed with a 200-bp window sliding along a step size of 20 bp ([@ref-24]).

Results
=======

PCV2 detection
--------------

Of the 685 samples collected from 90 different swine herds located in Fujian province from 2013 to 2017, 356 samples from 84 different swine herds were positive for PCV2. Ninety-five positive samples were selected for further analysis of PCV2 characteristics ([Table 1](#table-1){ref-type="table"}).

Phylogenetic analysis of ORF2
-----------------------------

Phylogenetic analysis based on ORF2 showed that Fujian PCV2 strains were classified into five subtypes (PCV2a, PCV2b, PCV2d, and PCV2e) ([Fig. 2](#fig-2){ref-type="fig"}). Among Fujian PCV2 strains, 7.37% (7/95) of the sequences corresponded to PCV2a, 15.8% (15/95) to PCV2b, 72.6% (69/95) to PCV2d, and 2.1% (2/95) to PCV2e. PCV2-CN-FuJian-612-2017 and PCV2-CN-FuJian-625-2017 were classified as PCV2e, which has been reported for the first time in China. Interestingly, PCV2-FJ-water DNA comes from contaminated water instead of from infected animals.

10.7717/peerj.4476/table-1

###### List of Fujian PCV2 samples in this study.

![](peerj-06-4476-g004)

  Name                      Geographic origin   Source              Time   Genetype   Accession No.
  ------------------------- ------------------- ------------------- ------ ---------- ----------------------------------------------------------
  CN-FJ-C1-2017             Putian              lymph node          2017   PCV2d      [MF679546](http://www.ncbi.nlm.nih.gov/nuccore/MF679546)
  CN-FJ-C008                Putian              serum               2017   PCV2a      [MF679547](http://www.ncbi.nlm.nih.gov/nuccore/MF679547)
  CN-FJ-N001-2011           Longayan            lymph node          2011   PCV2d      [MF679548](http://www.ncbi.nlm.nih.gov/nuccore/MF679548)
  CN-FJ-C8-2017             Longayan            Spleen/Lung         2017   PCV2a      [MF679549](http://www.ncbi.nlm.nih.gov/nuccore/MF679549)
  CN-FJ-C3-2017             Longayan            lymph node          2017   PCV2d      [MF679550](http://www.ncbi.nlm.nih.gov/nuccore/MF679550)
  CN-FJ-6S-2017             Zhangzhou           lymph node          2017   PCV2d      [MF679551](http://www.ncbi.nlm.nih.gov/nuccore/MF679551)
  CN-FJ-7SC-2017            Putian              serum               2017   PCV2d      [MF679552](http://www.ncbi.nlm.nih.gov/nuccore/MF679552)
  CN-FJ-F8C-2017            Xiamen              lymph node          2017   PCV2d      [MF679553](http://www.ncbi.nlm.nih.gov/nuccore/MF679553)
  CN-FJ-LY01-2016           Quanzhou            Lung                2016   PCV2d      [MF679554](http://www.ncbi.nlm.nih.gov/nuccore/MF679554)
  CN-FJ-LY03-2016           Ningde              lymph node          2016   PCV2d      [MF679555](http://www.ncbi.nlm.nih.gov/nuccore/MF679555)
  PCV2-FJ-3                 Ningde              serum               2013   PCV2b      [MG229682](http://www.ncbi.nlm.nih.gov/nuccore/MG229682)
  FJ01                      Longyan             lymph node          2013   PCV2a      [MG252966](http://www.ncbi.nlm.nih.gov/nuccore/MG252966)
  FJ02                      Zhangzhou           Spleen/Lung         2014   PCV2d      [MG229674](http://www.ncbi.nlm.nih.gov/nuccore/MG229674)
  FJ03                      Xiamen              lymph node          2014   PCV2d      [MG229681](http://www.ncbi.nlm.nih.gov/nuccore/MG229681)
  FJ04                      Nanping             lymph node          2013   PCV2d      [MG229675](http://www.ncbi.nlm.nih.gov/nuccore/MG229675)
  FJ05                      Fuzhou              lymph node          2014   PCV2d      [MG229676](http://www.ncbi.nlm.nih.gov/nuccore/MG229676)
  FJ06                      Longyan             serum               2013   PCV2d      [MG229677](http://www.ncbi.nlm.nih.gov/nuccore/MG229677)
  FJ07                      Quanzhou            lymph node          2013   PCV2d      [MG229678](http://www.ncbi.nlm.nih.gov/nuccore/MG229678)
  FJ08                      Zhangzhou           Lung                2013   PCV2d      [MG229679](http://www.ncbi.nlm.nih.gov/nuccore/MG229679)
  FJ09                      Longyan             lymph node          2013   PCV2b      [MG252967](http://www.ncbi.nlm.nih.gov/nuccore/MG252967)
  FJ10                      Nanping             lymph node          2014   PCV2b      [MG229680](http://www.ncbi.nlm.nih.gov/nuccore/MG229680)
  CN-FJ-LY04-2016           Quanzhou            serum               2016   PCV2b      [MF679556](http://www.ncbi.nlm.nih.gov/nuccore/MF679556)
  CN-FJ-NP01-2016           Nanping             lymph node          2016   PCV2d      [MF679557](http://www.ncbi.nlm.nih.gov/nuccore/MF679557)
  CN-FJ-NP02-2016           Nanping             Spleen/Lung         2016   PCV2d      [MF679558](http://www.ncbi.nlm.nih.gov/nuccore/MF679558)
  CN-FJ-NP03-2016           Nanping             lymph node          2016   PCV2d      [MF679605](http://www.ncbi.nlm.nih.gov/nuccore/MF679605)
  FJ-NP04-2017              Nanping             serum               2016   PCV2d      [MF679559](http://www.ncbi.nlm.nih.gov/nuccore/MF679559)
  CN-FJ-ZZ01-2016           Zhangzhou           lymph node          2016   PCV2d      [MF679560](http://www.ncbi.nlm.nih.gov/nuccore/MF679560)
  CN-FJ-ZZ02-2016           Zhangzhou           Spleen/Lung         2016   PCV2d      [MF679561](http://www.ncbi.nlm.nih.gov/nuccore/MF679561)
  CN-FJ-ZZ03-2016           Zhangzhou           lymph node          2016   PCV2d      [MF679562](http://www.ncbi.nlm.nih.gov/nuccore/MF679562)
  CN-FJ-ZZ04-2017           Zhangzhou           Lung                2017   PCV2d      [MF679563](http://www.ncbi.nlm.nih.gov/nuccore/MF679563)
  CN-FJ-N002-2012           Quanzhou            lymph node          2012   PCV2d      [MF679564](http://www.ncbi.nlm.nih.gov/nuccore/MF679564)
  CN-FJ-ZZ05-2017           Zhangzhou           spleen              2017   PCV2d      [MF679565](http://www.ncbi.nlm.nih.gov/nuccore/MF679565)
  CN-FJ-ZZ06-2017           Zhangzhou           lymph node          2017   PCV2d      [MF679566](http://www.ncbi.nlm.nih.gov/nuccore/MF679566)
  CN-FJ-C011                Xiamen              serum               2015   PCV2d      [MF679575](http://www.ncbi.nlm.nih.gov/nuccore/MF679575)
  CN-FJ-Z11                 Xiamen              lymph node          2017   PCV2d      [MF679567](http://www.ncbi.nlm.nih.gov/nuccore/MF679567)
  CN-FJ-ZZ12                Xiamen              serum               2015   PCV2d      [MF679568](http://www.ncbi.nlm.nih.gov/nuccore/MF679568)
  CN-FJ-C12                 Xiamen              lymph node          2016   PCV2d      [MF679569](http://www.ncbi.nlm.nih.gov/nuccore/MF679569)
  CN-FJ-C13                 Quanzhou            Lung                2015   PCV2d      [MF679570](http://www.ncbi.nlm.nih.gov/nuccore/MF679570)
  CN-FJ-C14                 Longyan             Spleen/Lung         2015   PCV2d      [MF679571](http://www.ncbi.nlm.nih.gov/nuccore/MF679571)
  CN-FJ-CFI                 Longyan             lymph node          2013   PCV2d      [MF679572](http://www.ncbi.nlm.nih.gov/nuccore/MF679572)
  CN-FJ-TETN                Longyan             serum               2013   PCV2b      [MF679573](http://www.ncbi.nlm.nih.gov/nuccore/MF679573)
  CN-FJ-TEI                 Quanzhou            serum               2013   PCV2d      [MF679574](http://www.ncbi.nlm.nih.gov/nuccore/MF679574)
  CN-FJ-CP11                Quanzhou            lymph node          2015   PCV2d      [MF679576](http://www.ncbi.nlm.nih.gov/nuccore/MF679576)
  CN-FJ-CA01                Quanzhou            lymph node          2016   PCV2d      [MF679577](http://www.ncbi.nlm.nih.gov/nuccore/MF679577)
  CN-FJ-CAE6                Quanzhou            spleen              2017   PCV2d      [MF679578](http://www.ncbi.nlm.nih.gov/nuccore/MF679578)
  CN-FJ-C0113               Zhangzhou           lymph node          2015   PCV2d      [MF679579](http://www.ncbi.nlm.nih.gov/nuccore/MF679579)
  CN-FJ-C1134               Xiamen              serum               2016   PCV2d      [MF679580](http://www.ncbi.nlm.nih.gov/nuccore/MF679580)
  CN-FJ-CTS02               Longyan             lymph node          2014   PCV2d      [MF679581](http://www.ncbi.nlm.nih.gov/nuccore/MF679581)
  CN-FJ-CTS03               Longyan             lymph node          2016   PCV2d      [MF679582](http://www.ncbi.nlm.nih.gov/nuccore/MF679582)
  CN-FJ-CTS04               Longyan             Spleen/Lung         2015   PCV2d      [MF679583](http://www.ncbi.nlm.nih.gov/nuccore/MF679583)
  CN-FJ-FZT01               Xiamen              lymph node          2014   PCV2b      [MF679584](http://www.ncbi.nlm.nih.gov/nuccore/MF679584)
  CN-FJ-FZC41               Quanzhou            serum               2015   PCV2b      [MF679585](http://www.ncbi.nlm.nih.gov/nuccore/MF679585)
  CN-FJ-FZOU                Ningde              lymph node          2013   PCV2d      [MF679586](http://www.ncbi.nlm.nih.gov/nuccore/MF679586)
  CN-FJ-FZCP4               Ningde              lymph node          2014   PCV2d      [MF679587](http://www.ncbi.nlm.nih.gov/nuccore/MF679587)
  CN-FJ-FZ01134             Ningde              Spleen/Lung         2014   PCV2d      [MF679588](http://www.ncbi.nlm.nih.gov/nuccore/MF679588)
  CN-FJ-FCP0712             Ningde              lymph node          2015   PCV2d      [MF679589](http://www.ncbi.nlm.nih.gov/nuccore/MF679589)
  PCV2-FJ-FJ5               Quanzhou            spleen              2016   PCV2d      [MF679590](http://www.ncbi.nlm.nih.gov/nuccore/MF679590)
  PCV2-FJ-TW01              Quanzhou            lymph node          2017   PCV2d      [MF679591](http://www.ncbi.nlm.nih.gov/nuccore/MF679591)
  PCV2-FJ-FT02              Putian              lymph node          2015   PCV2b      [MF679592](http://www.ncbi.nlm.nih.gov/nuccore/MF679592)
  PCV2-FJ-4129              Putian              Spleen/Lung         2016   PCV2d      [MF679593](http://www.ncbi.nlm.nih.gov/nuccore/MF679593)
  PCV2-FJ-17117             Putian              lymph node          2016   PCV2d      [MF679594](http://www.ncbi.nlm.nih.gov/nuccore/MF679594)
  PCV2-FJ-20131             Putian              lymph node          2016   PCV2d      [MF679595](http://www.ncbi.nlm.nih.gov/nuccore/MF679595)
  PCV2-FJ-water             Longyan             Water               2017   PCV2d      [MF679596](http://www.ncbi.nlm.nih.gov/nuccore/MF679596)
  PCV2-FJ-7117P             Putian              lymph node          2016   PCV2d      [MF679597](http://www.ncbi.nlm.nih.gov/nuccore/MF679597)
  CN-FJ-N005-2013           Zhangzhou           serum               2013   PCV2d      [MF679598](http://www.ncbi.nlm.nih.gov/nuccore/MF679598)
  CN-FJ-N004-2012           Fuzhou              lymph node          2012   PCV2d      [MF679599](http://www.ncbi.nlm.nih.gov/nuccore/MF679599)
  CN-FJ-N003-2012           Nanping             Lung                2012   PCV2d      [MF679600](http://www.ncbi.nlm.nih.gov/nuccore/MF679600)
  CN-FJ-3M-2017             Nanping             lymph node          2017   PCV2a      [MF679601](http://www.ncbi.nlm.nih.gov/nuccore/MF679601)
  CN-FJ-DD6-2017            Fuzhou              lymph node          2017   PCV2b      [MF679602](http://www.ncbi.nlm.nih.gov/nuccore/MF679602)
  CN-FJ-LG-2017             Longyan             Lung                2017   PCV2d      [MF679603](http://www.ncbi.nlm.nih.gov/nuccore/MF679603)
  PCV2-CN/FuJian-612-2017   Longyan             lymph node/spleen   2017   PCV2e      [MF589523](http://www.ncbi.nlm.nih.gov/nuccore/MF589523)
  PCV2-CN/FuJian-625-2017   Longyan             lymph node/spleen   2017   PCV2e      [MF589524](http://www.ncbi.nlm.nih.gov/nuccore/MF589524)
  PCV2-FJ-SS                Fuzhou              lymph node          2013   PCV2d      [MF589525](http://www.ncbi.nlm.nih.gov/nuccore/MF589525)
  PCV2-FJ-S2                Nanping             Spleen/Lung         2014   PCV2a      [MF589526](http://www.ncbi.nlm.nih.gov/nuccore/MF589526)
  PCV2-FJ-YE                Longyan             lymph node          2012   PCV2d      [MF589527](http://www.ncbi.nlm.nih.gov/nuccore/MF589527)
  PCV2-FJ-65                Longyan             Lung                2017   PCV2b      [MF589528](http://www.ncbi.nlm.nih.gov/nuccore/MF589528)
  PCV2-FJ-SO                Longyan             lymph node          2016   PCV2d      [MF589529](http://www.ncbi.nlm.nih.gov/nuccore/MF589529)
  PCV2-FJ-02                Longyan             Spleen/Lung         2013   PCV2d      [MF589530](http://www.ncbi.nlm.nih.gov/nuccore/MF589530)
  PCV2-FJ-03                Longyan             lymph node          2014   PCV2b      [MF589531](http://www.ncbi.nlm.nih.gov/nuccore/MF589531)
  PCV2-FJ-S3                Longyan             serum               2015   PCV2b      [MF589532](http://www.ncbi.nlm.nih.gov/nuccore/MF589532)
  PCV2-FJ-S4                Longyan             lymph node          2014   PCV2d      [MF589533](http://www.ncbi.nlm.nih.gov/nuccore/MF589533)
  PCV2-FJ-S1                Fuzhou              lymph node          2014   PCV2a      [MF589534](http://www.ncbi.nlm.nih.gov/nuccore/MF589534)
  PCV2-FJ-MAO               Fuzhou              Lung                2013   PCV2b      [MF589535](http://www.ncbi.nlm.nih.gov/nuccore/MF589535)
  PCV2-FJ-T10               Fuzhou              lymph node          2014   PCV2d      [MF589536](http://www.ncbi.nlm.nih.gov/nuccore/MF589536)
  PCV2-FJ-S22               Fuzhou              Spleen/Lung         2016   PCV2d      [MF589537](http://www.ncbi.nlm.nih.gov/nuccore/MF589537)
  PCV2-FJ-06                Fuzhou              Lung                2017   PCV2a      [MF589538](http://www.ncbi.nlm.nih.gov/nuccore/MF589538)
  PCV2-FJ-LY6               Zhangzhou           lymph node          2014   PCV2d      [MF589539](http://www.ncbi.nlm.nih.gov/nuccore/MF589539)
  PCV2-FJ-TI                Zhangzhou           Spleen              2014   PCV2d      [MF589540](http://www.ncbi.nlm.nih.gov/nuccore/MF589540)
  PCV2-FJ-EX                Zhangzhou           lymph node          2015   PCV2d      [MF589541](http://www.ncbi.nlm.nih.gov/nuccore/MF589541)
  PCV2-FJ-TN                Zhangzhou           lymph node          2015   PCV2d      [MF589542](http://www.ncbi.nlm.nih.gov/nuccore/MF589542)
  PCV2-FJ-SY                Longyan             lymph node          2015   mPCV2d     [MF589543](http://www.ncbi.nlm.nih.gov/nuccore/MF589543)
  PCV2-FJ-01                Quanzhou            serum               2016   PCV2d      [MF589544](http://www.ncbi.nlm.nih.gov/nuccore/MF589544)
  PCV2-FJBZ05               Longyan             lymph node          2015   PCV2b      [MG011720](http://www.ncbi.nlm.nih.gov/nuccore/MG011720)
  CN-PCV2-FJ1145            Longyan             Spleen/Lung         2016   mPCV2b     [MG011721](http://www.ncbi.nlm.nih.gov/nuccore/MG011721)
  PCV2-FJLY10               Longyan             lymph node          2016   PCV2b      [MG011722](http://www.ncbi.nlm.nih.gov/nuccore/MG011722)

![Neighbor-joining (NJ) phylogenetic analysis of Fujian PCV2 ORF2 genes.\
Reliability of the tree was assessed by bootstrap analysis of 1,000 replications. PCV2b (GenBank accession no. [AF055394](http://www.ncbi.nlm.nih.gov/nuccore/AF055394)).](peerj-06-4476-g002){#fig-2}

Amino acid analysis of ORF2
---------------------------

The lengths of the Fujian PCV2 ORF2 sequences were 702 nt (PCV2a, PCV2b, or PCV2d), 705 nt (PCV2c and PCV2d), and 717 nt (PCV2e), which encoded Cap proteins of 233, 234, and 238 amino acids, respectively. These 95 isolates shared approximately 78.7%--100% nucleotide identity and 74.5%--100% amino acid identity for ORF2. Amino acid alignments showed that the Cap protein of PCV2e and two strains (CN-FJ-CTS04 and FJ-6S-2017) differed markedly from those of PCV2a, PCV2b, PCV2c, and PCV2d. Unlike the sequence of other known PCV2 ORF2, the PCV2e ORF2 possesses 12 or 15 additional nts, which generate a terminal seven amino acid sequence (PPPLSYM) that is different from the PK and NPK termini of the 233 and 234 amino acid capsids, respectively ([@ref-6]). The PCV2 strains in genotype PCV2d harbored four unique amino acid mutations (Y^8^ → F/T^8^, A^68^ → N^68^, F^53^ → I^53^, and V^215^ → I^215^), whereas PCV2 in genotype PCV2e harbored ten unique amino acid mutations (K^58^ → V^8^, D^115^ → E^115^, A^133^ → T^133^, A^135^ → N^135^, T^137^ →  S^137^, T^170^ → I^170^, V^196^ → T^196^, N^204^ → H^204^, Y^207^ →  T^207^ and L^226^ → M^226^).

Recombination analysis
----------------------

Seven methods (RDP, GeneConv, BootScan, MaxChi, Chimera, SiScan, and 3Seq) were implemented in RDP 4.24 to detect potential recombinants. The results showed that inter-genotypic (PCV2-FJ-SY) and intra-genotypic (CN-PCV2-FJ1145) recombination events of PCV2 have been detected ([Fig. 3](#fig-3){ref-type="fig"}). Additionally, the results of SIMPLOT software (v3.5.1) confirmed the putative recombinant events obtained with the RDP 4.24 software.

![Recombination analysis of the PCV2 ORF2 gene of PCV2-FJ-SY (A) and CN-PCV2-FJ1145 (B) using a sliding window of 200 nt moving in 20 nt steps.\
Recombination events were analyzed by Simplot software (v. 3.5.1). A PCV1 isolate ([KJ408798](http://www.ncbi.nlm.nih.gov/nuccore/KJ408798)) was used as outgroup.](peerj-06-4476-g003){#fig-3}

Discussion
==========

PCV2 has been prevalent in Chinese swine herds since it was first identified in China in 1999. Previous studies demonstrated that various PCV2 genotypes exist in China, including PCV2a, PCV2b, PCV2c, PCV2d, and a minor recombinant group. Surprisingly, different PCV2 genotypes or strains have co-existed in Chinese swine herds. Currently, the amount of live pigs in the Fujian province (Southeast China) is \>20 million heads, although the epidemic status and genetic diversity of PCV2 is still unknown. Thus, we sought to investigate the genetic diversity and epidemiology of PCV2 in southeast China in 2013--2017.

On the basis of ORF2 nucleotide sequences, the genotypes of Fujian PCV2 have been classified as PCV2a, PCV2b, PCV2d, and PCV2e ([@ref-27]; [@ref-14]; [@ref-13]; [@ref-16]; [@ref-6]), of which, PCV2d was predominant in Fujian from 2014 to 2017. The present data indicate that the prevalence of PCV2d increased from 57.1% in 2013 to 87.5% in 2016, suggesting that PCV2d has replaced PCV2b and has now become the predominant PCV2 genotype in Fujian since 2013. Additionally, CN-FJ-CTS04 and FJ-6S-2017 strains emerged in cases of in cases of apparent vaccine failure. Overuse of vaccine has probably contributed to the variation of PCV2. PCV2e, a new PCV2 genotype, was identified in the USA in 2015, the ORF2 sequence of which contains 12 or 15 additional nt compared to other known PCV2 ORF2 sequences and shows approximately 85% identity with other known PCV2 ORF2 sequences ([@ref-16]; [@ref-6]). In the present study, only two PCV2e sequences were detected in Fujian, suggesting that PCV2e replication is low in the swine herds. The group members encoded a capsid protein of 238 amino acids, which is markedly different from all known capsid proteins of 233 or 234 amino acids ([@ref-36]). The pathogenicity of PCV2e warrants further investigation.

Recently, several groups detected PCV2 DNA in water samples, human stool, beef, calf bone marrow, farm air, house flies, and mosquito ([@ref-33]; [@ref-2]; [@ref-11]; [@ref-37]). In the present study, PCV2 DNA was also detected in river water, which is indicative of a potential human health hazard.

PCV2 nucleotide substitution rate has been calculated to vary between 1.2 × 10^−3^ and 6.6 × 10^−3^ substitutions/site/year, which is close to that of RNA viruses ([@ref-8]; [@ref-29]). Recombination is critical for viral evolution, and recombination events between PCV2 strains could generate PCV2 of varying pathogenicity ([@ref-26]; [@ref-17]; [@ref-34]). Both inter-genotypic and intra-genotypic recombination events of PCV2 have been recorded; inter-genotypic recombination occurs within ORF1 and ORF2, whereas intra-genotypic recombination mainly occurs within ORF2. Recently, a PCV2c genotype strain (GenBank accession no. [KC823058](http://www.ncbi.nlm.nih.gov/nuccore/KC823058)) was reported in China, and three strains were generated from PCV2b and PCV2c recombination ([@ref-23]). In the present study, we detected that one natural strain (PCV2-FJ-SY) was generated by recombination between different lineages of PCV2, while CN-PCV2-FJ1145 was generated by intra-genotypic recombination. These results indicated that PCV2 is continuously evolving through genome recombination, which leads to rapid emergence of new variant stains.

In summary, PCV2a, PCV2b, PCV2d, and PCV2e co-exist in Fujian, and PCV2d-2 is the predominant strain that has been circulating in Fujian since 2013. Our results enhance the understanding of the PCV2 epidemic in Fujian, and may assist veterinary workers in establishing suitable prevention and control policies for the novel strains emerging from viral evolution.

Conclusions
===========

The findings of this study demonstrated that PCV2 is ubiquitous in China, with PCV2d being the predominant strain circulating from 2013 to 2017. PCV2 is continuously evolving through genome recombination or new viral introductions from distant geographic regions, which leads to rapid emergence of new variant stains.
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